A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a
new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is
the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.